[6][4][7] He published a number of medical papers, including "Cloning and characterization of mouse brush border myosin-I in adult and embryonic intestine.
[2][12] After leaving his residency Skowron worked as a healthcare analyst at SAC Capital Management in Stamford, Connecticut, and then at Millennium Partners in New York, for less than one year at each.
[15][16][4] He joined FrontPoint in 2003, co-founding its health care team and taking on the title of managing director at Morgan Stanley, its owner, which bought the firm for $400 million in 2006.
[16][4][21] At first Skowron denied the charges against him, and his defense attorney said he would plead not guilty, saying "We look forward to responding to the allegations more fully in court at the appropriate time".
[6] The U.S. Attorney charged the consultant with tipping Skowron material, non-public information concerning pharmaceutical company Human Genome Science's clinical trial.
[16] In August 2011, Skowron pleaded guilty in federal court in Manhattan to conspiracy to engage in insider trading and obstruction of justice.
[1][25] Preet Bharara, U.S. Attorney for the Southern District of New York, said: "Chip Skowron is the latest example of a portfolio manager willing to pay for proprietary, non-public information that gave him an illegal trading edge over the average investor.
My wife and my children endured extraordinary embarrassment, isolation, and absence because of my choices because of the empire I thought I needed to build.
"[27] She noted further: "In addition to exposing Morgan Stanley to government investigations to and direct financial losses, Skowron's behavior damaged the firm's reputation, a valuable corporate asset".